Mode
Text Size
Log in / Sign up

rTMS shows no significant benefit over sham for treatment-resistant schizophreniaTrial shows no clear benefit from magnetic brain stimulation

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret rTMS for treatment-resistant schizophrenia as lacking consistent evidence of benefit over sham.

This meta-analysis synthesized data from randomized controlled trials evaluating repetitive transcranial magnetic stimulation (rTMS) versus sham stimulation in adults with treatment-resistant schizophrenia. The primary outcome was global symptom severity, with secondary outcomes including negative symptoms and auditory hallucinations.

For overall symptom severity measured by PANSS, the pooled effect was not statistically significant (SMD 0.14; 95% CI -0.26 to 0.54). Similarly, negative symptoms showed no significant improvement (SMD 0.37; 95% CI -0.12 to 0.86), and auditory hallucinations assessed by AHRS also did not reach significance (SMD -0.03; 95% CI -0.26 to 0.20).

The authors noted substantial heterogeneity for PANSS and negative symptom outcomes, and subgroup findings were exploratory and should be interpreted cautiously. Safety data were not reported, limiting assessment of tolerability.

Current evidence does not support a consistent therapeutic benefit of rTMS over sham for symptom reduction in treatment-resistant schizophrenia. Clinicians should interpret these findings with caution given the lack of statistical significance and heterogeneity across studies.

How this fits prior evidence

This meta-analysis extends prior coverage of rTMS for mental disorders by specifically focusing on treatment-resistant schizophrenia and finding no significant benefit over sham. It contrasts with earlier reports suggesting rTMS shows potential for various mental disorders, though those were based largely on preclinical data. The null results also contrast with the promising but preliminary evidence for transcranial focused ultrasound in schizophrenia. The findings highlight the gap between exploratory subgroup analyses and definitive evidence, reinforcing the need for standardized protocols as noted for dynamic gratings.

Living with treatment-resistant schizophrenia is incredibly difficult. When standard medications do not work, families often look for alternative treatments to manage severe symptoms like hallucinations or a lack of emotional expression. One such method is repetitive transcranial magnetic stimulation (rTMS), which uses magnets to stimulate specific areas of the brain.

A large review of several trials looked at whether this magnetic treatment actually helped patients compared to a sham, or fake, treatment. The researchers analyzed how well it reduced overall symptoms, as well as specific issues like hearing voices and feeling emotionally distant. They found that rTMS did not show a statistically significant improvement over the sham treatment in any of these categories.

The findings suggest that we cannot yet rely on this method to consistently reduce symptoms for those with schizophrenia who do not respond well to medication. Because the data was varied across different studies, it is still early to know if specific settings could change these results. For now, the evidence does not support rTMS as a reliable way to improve daily life for these patients.

What this means for you:
Current evidence shows that magnetic brain stimulation does not consistently improve symptoms in treatment-resistant schizophrenia.

Common questions

Does magnetic brain stimulation help with hallucinations?

The study looked specifically at auditory hallucinations, which are voices people hear. The results showed no statistically significant improvement when using repetitive transcranial magnetic stimulation compared to a sham treatment. Because the evidence is not consistent, it is best to talk to a doctor about specific treatment plans.

Is this treatment effective for those who don't respond to meds?

The study focused on adults with treatment-resistant schizophrenia. The findings showed that the magnetic stimulation did not provide a statistically significant improvement in overall symptom severity compared to sham stimulation. This means it is not currently proven as a reliable alternative for these patients.

What are the specific symptoms this study looked at?

The researchers looked at three main areas: overall symptom severity, negative symptoms (like feeling emotionally distant), and auditory hallucinations. In all three categories, the magnetic stimulation did not show a significant improvement over the sham treatment.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
BackgroundTreatment-resistant schizophrenia (TRS) affects up to one-third of individuals with schizophrenia and remains a major clinical challenge despite optimized pharmacotherapy. Repetitive transcranial magnetic stimulation (rTMS) has been proposed as a neuro-modulatory intervention for refractory symptoms, yet evidence specific to TRS remains limited and inconsistent.ObjectivesTo evaluate the efficacy and safety of rTMS for reducing global symptom severity, negative symptoms, and auditory hallucinations in adults with treatment-resistant schizophrenia, and to examine the influence of stimulation parameters on treatment outcomes.MethodsA systematic review and meta-analysis was conducted following PRISMA guidelines and registered with PROSPERO (CRD420251143558). Eight electronic databases were searched up to 10th September 2025. Randomized controlled trials including adults with TRS and comparing rTMS with sham stimulation were eligible. Standardized mean differences (Hedges’ g) were pooled using REML-based random-effects models. Heterogeneity and subgroup effects were examined, and publication bias was explored through visual inspection of funnel plots.ResultsAcross included trials, rTMS was not associated with statistically significant improvements in overall symptom severity measured by PANSS (SMD 0.14, 95% CI −0.26 to 0.54), negative symptoms (SMD 0.37, 95% CI −0.12 to 0.86), or auditory hallucinations measured by AHRS (SMD −0.03, 95% CI −0.26 to 0.20), based on post-treatment outcome scores. Substantial heterogeneity was observed for PANSS and negative symptoms, while heterogeneity for AHRS was low. Subgroup findings were exploratory and should be interpreted cautiously.ConclusionsCurrent evidence does not support a consistent therapeutic benefit of rTMS over sham stimulation for symptom reduction in treatment-resistant schizophrenia. While some subgroup analyses suggested variability in effect estimates across stimulation protocols, these findings were exploratory and should be interpreted with caution. Further large-scale, well-designed trials are needed to clarify the role of rTMS in this population.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251143558, identifier CRD420251143558.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.